Compare AstraZeneca plc (AZN) vs Vistra Corp (VST) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Vistra Corp. (VST) trades at $158.12, down 0.47% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings beating estimates, with revenue growth from $17.74B in 2025 to $19.4B projected for 2026. Net income margin improved to 11.52%, supported by robust cash flow from operations of $4.07B. Recent news highlights Vistra's positioning in the AI power demand surge and long-term power purchase agreements with major tech firms.

Outlook remains positive with a consensus price target of $230.50, implying significant upside. Key opportunities include exposure to growing electricity demand and strategic renewables focus. Risks involve power-price volatility, high debt levels, and execution of growth projects. Analyst sentiment is strongly bullish with 91% buy ratings, though investors should monitor Q2 2026 earnings due August 7 for confirmation of growth trajectory.